hr-810 and Kidney-Failure--Chronic

hr-810 has been researched along with Kidney-Failure--Chronic* in 2 studies

Other Studies

2 other study(ies) available for hr-810 and Kidney-Failure--Chronic

Article	Year
Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes. Clinical pharmacology and therapeutics, 1996, Volume: 60, Issue:6 Cefpirome is a cephalosporin eliminated primarily by kidneys that requires dosage reduction in patients with renal failure. The pharmacokinetic parameters were studied in 10 patients with end-stage renal disease who were receiving hemodialysis. Repeated intravenous administration of 2 gm cefpirome three times a week resulted in trough levels of 12.2 +/- 5.4 micrograms/ml and peak serum concentrations of 99.6 +/- 82.1 micrograms/ml. After 3 1/2 hours of hemodialysis with polysulfone high-flux membranes, 62.3% +/- 23.3% of cefpirome was removed. The interdialytic half-life was 9.35 +/- 0.99 hours, and the intradialytic half-life was 2.02 +/- 0.7 hours. Topics: Adult; Aged; Cefpirome; Cephalosporins; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Membranes, Artificial; Middle Aged; Polymers; Renal Dialysis; Sulfones	1996
Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and in patients treated by continuous ambulatory peritoneal dialysis. Clinical pharmacology and therapeutics, 1993, Volume: 54, Issue:4 Cefpirome is eliminated primarily by renal excretion, compelling dosage reduction in kidney failure. We studied the elimination kinetics after intravenous administration of 1 gm cefpirome in patients undergoing hemodialysis (n = 9) and after intravenous (n = 6) or intraperitoneal administration (n = 6) of 1 gm cefpirome in subjects treated by continuous ambulatory peritoneal dialysis (CAPD). Four hours of hemodialysis removed 48% +/- 9% of the drug present in the body at the start of hemodialysis. Consequently, a supplementary dose equal to 50% of the daily dose recommended in end stage renal disease (ESRD) should be administered after each hemodialysis treatment. In patients receiving CAPD, therapeutic levels in both serum and dialysate were reached after intravenous and intraperitoneal administration. The bioavailability after intraperitoneal administration was 84%. After systemic administration, the elimination of cefpirome in the dialysate was negligible. Consequently, systemic dosage of cefpirome in patients receiving CAPD and in patients with ESRD should be identical. Topics: Adult; Aged; Biological Availability; Cefpirome; Cephalosporins; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Models, Biological; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis	1993

Article

Year

Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes.

Clinical pharmacology and therapeutics, 1996, Volume: 60, Issue:6

Cefpirome is a cephalosporin eliminated primarily by kidneys that requires dosage reduction in patients with renal failure. The pharmacokinetic parameters were studied in 10 patients with end-stage renal disease who were receiving hemodialysis. Repeated intravenous administration of 2 gm cefpirome three times a week resulted in trough levels of 12.2 +/- 5.4 micrograms/ml and peak serum concentrations of 99.6 +/- 82.1 micrograms/ml. After 3 1/2 hours of hemodialysis with polysulfone high-flux membranes, 62.3% +/- 23.3% of cefpirome was removed. The interdialytic half-life was 9.35 +/- 0.99 hours, and the intradialytic half-life was 2.02 +/- 0.7 hours.

Topics: Adult; Aged; Cefpirome; Cephalosporins; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Membranes, Artificial; Middle Aged; Polymers; Renal Dialysis; Sulfones

1996

Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and in patients treated by continuous ambulatory peritoneal dialysis.

Clinical pharmacology and therapeutics, 1993, Volume: 54, Issue:4

Cefpirome is eliminated primarily by renal excretion, compelling dosage reduction in kidney failure. We studied the elimination kinetics after intravenous administration of 1 gm cefpirome in patients undergoing hemodialysis (n = 9) and after intravenous (n = 6) or intraperitoneal administration (n = 6) of 1 gm cefpirome in subjects treated by continuous ambulatory peritoneal dialysis (CAPD). Four hours of hemodialysis removed 48% +/- 9% of the drug present in the body at the start of hemodialysis. Consequently, a supplementary dose equal to 50% of the daily dose recommended in end stage renal disease (ESRD) should be administered after each hemodialysis treatment. In patients receiving CAPD, therapeutic levels in both serum and dialysate were reached after intravenous and intraperitoneal administration. The bioavailability after intraperitoneal administration was 84%. After systemic administration, the elimination of cefpirome in the dialysate was negligible. Consequently, systemic dosage of cefpirome in patients receiving CAPD and in patients with ESRD should be identical.

Topics: Adult; Aged; Biological Availability; Cefpirome; Cephalosporins; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Models, Biological; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis

1993